Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update - Choueiri, TK; Hessel, C; Halabi, S (Eur J Cancer, 2018)
et al.